Observational Study Investigating the Effectiveness of Fentanyl Matrix in Relieving Pain and Improving Function in Patients With Osteoarthritis of the Knee or Hip
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to investigate the utility of fentanyl matrix for the treatment of pain due to osteoarthritis (OA) of knee or hip, which was not adequately controlled by non-opioid analgesic (e.g. NSAIDs or COX-II inhibitors) or weak opioids [tramadol HClacetaminophen, tramadol or codeine (or combinations with acetaminophen/ibuprofen)].
| Condition | Intervention |
|---|---|
|
Pain Osteoarthritis, Hip Osteoarthritis, Knee |
Drug: fentanyl matrix |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Official Title: | Fentanyl Matrix for the Treatment of Pain Caused by Osteoarthritis of the Knee or Hip: Improvement of Pain and Function: Multicenter, Open-label, Prospective, Observational Study |
- Change in pain intensity from baseline through final evaluation as measured by Numeric Rating Scale [ Time Frame: Baseline and week 8 ] [ Designated as safety issue: No ]
- Improved pain relief as measured using the K-WOMAC scale [ Time Frame: baseline, week 4 and week 8 ] [ Designated as safety issue: No ]
- Improvement of sleep disturbance [ Time Frame: baseline, week 4 and week 8 ] [ Designated as safety issue: No ]
- Impact of activity of daily activities measured by 5-point likert scale and social activities measured by 5-point likert scale [ Time Frame: baseline, week 4 and week 8 ] [ Designated as safety issue: No ]
- Investigator and patient global assessment measured by 5-point likert scale [ Time Frame: Week 4 and week 8 ] [ Designated as safety issue: No ]
- Improved pain relief as measured using the CGI-I [ Time Frame: Week 4 and week 8 ] [ Designated as safety issue: No ]
| Enrollment: | 742 |
| Study Start Date: | August 2008 |
| Study Completion Date: | January 2009 |
| Primary Completion Date: | January 2009 (Final data collection date for primary outcome measure) |
| Groups/Cohorts | Assigned Interventions |
|---|---|
|
001
fentanyl matrix Knee osteoarthritis starting with 12mcg/h (flexible dose)
|
Drug: fentanyl matrix
Knee osteoarthritis, starting with 12mcg/h (flexible dose)
|
|
002
fentanyl matrix Hip osteoarthritis starting with 12mcg/h (flexible dose)
|
Drug: fentanyl matrix
Hip osteoarthritis, starting with 12mcg/h (flexible dose)
|
Detailed Description:
This study is a prospective, open-label, non-interventional study. The objective of this study is to investigate the utility of fentanyl matrix after 8 week treatment of fentanyl matrix for the treatment of pain due to osteoarthritis (OA) of knee or hip, which was not adequately controlled by non-opioid analgesic (e.g. NSAIDs or COX-II selective inhibitors) or weak opioids [tramadol HCl with acetaminophen, tramadol or codeine (or combination with acetaminophen/ibuprofen)] in clinical practice according to the investigator's discretion. This study will investigate the usefulness of fentanyl matrix based on improvement in pain and function after Fentanyl matrix administration in patients who complained of pain caused by osteoarthritis and indicated for Fentanyl matrix administration in clinical practice at the investigator's discretion. This study will also measure the patients' functional improvement through Korean Version of WOMAC. Observational study - No investigational drug administered
Eligibility| Ages Eligible for Study: | 20 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Probability Sample |
The study population is the patients who visit a center during the study period with the complaint of chronic pain caused by osteoarthritis of the knee or hip, and are deemed to fail to control pain in a proper way and need fentanyl matrix administration according to the investigator's discretion
Inclusion Criteria:
- Patients who complain of chronic pain caused by osteoarthritis of the knee or hip persisting for 3 months or longer
- Patients who can fully observe the overall clinical study requirements including K-WOMAC completion at the investigator's discretion
- Patients who complain of severe pain (NRS score = 7) because pain was not treated enough with the previous analgesic
- Patients who have never been administered strong opioid analgesics over the last one month
Exclusion Criteria:
- Patients with a history of the drug or alcohol abuse in the past or now
- Childbearing women who are pregnant or likely to be pregnant during the study period and male subjects who are neither infertile nor willing to refrain from sexual relations but whose partner does not conduct an effective contraception (implant, injections, oral contraceptives, intrauterine device, etc.)
- Patients who are unable to use a transdermal system due to skin disease
- Patients with serious mental disorder
- Patients with history of hypersensitivity to opioid analgesics
- Patients with history of CO2 retention
- Patients who are not eligible for the study participation based on warnings, precautions and contra medications in the package insert of the study drug at the investigator's discretion
Contacts and Locations More Information
No publications provided
| Responsible Party: | R&D Director, Janssen Korea, Ltd., Korea |
| ClinicalTrials.gov Identifier: | NCT01119885 History of Changes |
| Other Study ID Numbers: | CR015454 |
| Study First Received: | January 29, 2010 |
| Last Updated: | May 26, 2010 |
| Health Authority: | Korea: Food and Drug Administration |
Keywords provided by Janssen Korea, Ltd., Korea:
|
chronic pain fentanyl matrix arthritis osteoarthritis |
Additional relevant MeSH terms:
|
Osteoarthritis Osteoarthritis, Hip Osteoarthritis, Knee Arthritis Joint Diseases Musculoskeletal Diseases Rheumatic Diseases Fentanyl Adjuvants, Anesthesia Central Nervous System Agents Therapeutic Uses |
Pharmacologic Actions Narcotics Central Nervous System Depressants Physiological Effects of Drugs Analgesics Sensory System Agents Peripheral Nervous System Agents Anesthetics, Intravenous Anesthetics, General Anesthetics Analgesics, Opioid |
ClinicalTrials.gov processed this record on June 17, 2013